DNA Script, a South San Francisco, CA-based pioneer in Enzymatic DNA Synthesis (EDS) for on-demand DNA printing, completed its Series C financing, raising $200m of new capital.
With this latest financing, DNA Script has raised $315m since the company was founded in 2014. Accounts and funds advised by T. Rowe Price Associates and Baillie Gifford participated in the second tranche of the Series C, along with Healthcor Management, eureKARE, and Irving Investors. They joined Coatue Management, Catalio Capital Management, Fidelity Management & Research Company LLC, Columbia Threadneedle Investments, Casdin Capital, as well as other investors who participated in the first closing.
Proceeds from this financing will be used to advance the SYNTAX Platform, DNA Script’s first commercial product powered by its proprietary EDS technology.
Founded in 2014 by CEO Thomas Ybert, DNA Script is a life sciences technology company developing SYNTAX, which empowers scientists to print synthetic nucleic acids for genomics and molecular biology applications at the convenience of their lab bench. On-demand printing enables labs to iterate without waiting days or weeks to receive their genetic material from third-party service providers.